MAOB and Parkinson disease: How effective is the additional administration of MAO-B-inhibitors compared to placebo in the treatment of PD patients with fluctuations, and what differences exist regarding safety and tolerability of the approved MAO-B-inhibitors for the treatment of PD patients with fluctuations?